share_log

微創醫療：關連交易可換股貸款涉及根據特別授權發行換股股份

MICROPORT: CONNECTED TRANSACTION CONVERTIBLE LOAN INVOLVING THE ISSUE OF CONVERSION SHARES UNDER SPECIFIC MANDATE

香港交易所 ·  Apr 5 10:54
Summary by Moomoo AI
微創醫療科學有限公司（「微創醫疗」）於2024年4月5日宣布，為償還2026年到期的可換股債券未償還款項約448百萬美元，公司與原貸款人訂立了可換股融資協議。根據協議，原貸款人將提供150,000,000美元本金總額的美元可換股定期貸款融資，年利率為5.75%，並有選擇權進一步增加至200,000,000美元。該融資協議還包含一系列的表現目標，若未達成，可能導致提前償還貸款。此外，微創醫疗預計將獲得超過300百萬美元的信貸支持。可換股貸款將轉換為換股股份，初始換股價為每股7.46港元。微創醫疗將於2024年4月29日或之前向股東發送通函，並將在5月22日召開股東週年大會以考慮相關協議。該交易構成關連交易，需遵守上市規則第14A章的規定。
微創醫療科學有限公司（「微創醫疗」）於2024年4月5日宣布，為償還2026年到期的可換股債券未償還款項約448百萬美元，公司與原貸款人訂立了可換股融資協議。根據協議，原貸款人將提供150,000,000美元本金總額的美元可換股定期貸款融資，年利率為5.75%，並有選擇權進一步增加至200,000,000美元。該融資協議還包含一系列的表現目標，若未達成，可能導致提前償還貸款。此外，微創醫疗預計將獲得超過300百萬美元的信貸支持。可換股貸款將轉換為換股股份，初始換股價為每股7.46港元。微創醫疗將於2024年4月29日或之前向股東發送通函，並將在5月22日召開股東週年大會以考慮相關協議。該交易構成關連交易，需遵守上市規則第14A章的規定。
MicroChung Medical Sciences Limited (“MicroChung Medical”) announced on April 5, 2024 that it has entered into a convertible equity financing agreement with the original lender to repay approximately $448 million in outstanding repayment of convertible notes due 2026. Under the agreement, the original borrower will provide USD 150 million in convertible term loan financing with an annual interest rate of 5.75%, with an option to further increase to $200 million. The financing agreement also contains a series of performance targets that, if not met, may result in early repayment of the loan. IN ADDITION, MICRO MEDICAL IS EXPECTED TO RECEIVE MORE THAN $300 MILLION IN CREDIT SUPPORT. The convertible loan will be converted into convertible shares with an initial exchange price of HK$7.46 per share. Microchip Medical will send a circular to shareholders on or before April 29, 2024, and an Annual General Meeting will be held on May 22 to consider the relevant agreement. The transaction constitutes a connected transaction and is subject to the provisions of Chapter 14A of the Listing Rules.
MicroChung Medical Sciences Limited (“MicroChung Medical”) announced on April 5, 2024 that it has entered into a convertible equity financing agreement with the original lender to repay approximately $448 million in outstanding repayment of convertible notes due 2026. Under the agreement, the original borrower will provide USD 150 million in convertible term loan financing with an annual interest rate of 5.75%, with an option to further increase to $200 million. The financing agreement also contains a series of performance targets that, if not met, may result in early repayment of the loan. IN ADDITION, MICRO MEDICAL IS EXPECTED TO RECEIVE MORE THAN $300 MILLION IN CREDIT SUPPORT. The convertible loan will be converted into convertible shares with an initial exchange price of HK$7.46 per share. Microchip Medical will send a circular to shareholders on or before April 29, 2024, and an Annual General Meeting will be held on May 22 to consider the relevant agreement. The transaction constitutes a connected transaction and is subject to the provisions of Chapter 14A of the Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more